Is CAPR or QTTB more profitable?

Q32 Bio's return on equity of 149.23% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -59.27% -48.65% Q32 Bio N/A 149.23% 34.50%

Does the media refer more to CAPR or QTTB?

In the previous week, Q32 Bio had 4 more articles in the media than Capricor Therapeutics. MarketBeat recorded 5 mentions for Q32 Bio and 1 mentions for Capricor Therapeutics. Capricor Therapeutics' average media sentiment score of 1.16 beat Q32 Bio's score of 0.32 indicating that Capricor Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Q32 Bio 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CALT or QTTB?

Q32 Bio has a consensus target price of $22.33, suggesting a potential upside of 48.49%. Given Q32 Bio's stronger consensus rating and higher possible upside, analysts clearly believe Q32 Bio is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Q32 Bio 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has better valuation & earnings, QTTB or SDGR?

Q32 Bio has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Q32 Bio $53.74M 4.75 $29.82M $2.66 5.65 Schrodinger $255.87M 4.33 -$103.26M -$1.41 N/A

Is QTTB or SDGR more profitable?

Q32 Bio has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Q32 Bio's return on equity of 149.23% beat Schrodinger's return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 149.23% 34.50% Schrodinger -40.61% -30.85% -15.32%

Does the media favor QTTB or SDGR?

In the previous week, Q32 Bio had 4 more articles in the media than Schrodinger. MarketBeat recorded 5 mentions for Q32 Bio and 1 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.88 beat Q32 Bio's score of 0.32 indicating that Schrodinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Q32 Bio 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Schrodinger 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings & valuation, WVE or QTTB?

Q32 Bio has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio WAVE Life Sciences $42.73M 25.80 -$204.38M -$1.06 N/A Q32 Bio $53.74M 4.75 $29.82M $2.66 5.65

Is WVE or QTTB more profitable?

Q32 Bio has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. Q32 Bio's return on equity of 149.23% beat WAVE Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets WAVE Life Sciences -255.70% -56.76% -42.80% Q32 Bio N/A 149.23% 34.50%

Does the media refer more to WVE or QTTB?

In the previous week, Q32 Bio had 2 more articles in the media than WAVE Life Sciences. MarketBeat recorded 5 mentions for Q32 Bio and 3 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 1.37 beat Q32 Bio's score of 0.32 indicating that WAVE Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Q32 Bio 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, SVRA or QTTB?

Q32 Bio has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.56 N/A Q32 Bio $53.74M 4.75 $29.82M $2.66 5.65

Is SVRA or QTTB more profitable?

Q32 Bio's return on equity of 149.23% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -87.19% -66.42% Q32 Bio N/A 149.23% 34.50%

Q32 Bio (QTTB) Competitors

$15.04 -0.01 (-0.07%)

Closing price 04:00 PM Eastern

Extended Trading

$15.04 0.00 (-0.01%)

As of 07:57 PM Eastern

Compare

QTTB vs. CAPR, CALT, SDGR, WVE, and SVRA

Should you buy Q32 Bio stock or one of its competitors? MarketBeat compares Q32 Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Q32 Bio include Capricor Therapeutics (CAPR), Calliditas Therapeutics AB (publ) (CALT), Schrodinger (SDGR), WAVE Life Sciences (WVE), and Savara (SVRA). These companies are all part of the "pharmaceutical products" industry.

How does Q32 Bio compare to Capricor Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Q32 Bio's return on equity of 149.23% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-59.27%	-48.65%
Q32 Bio	N/A	149.23%	34.50%

Capricor Therapeutics presently has a consensus price target of $53.67, suggesting a potential upside of 175.21%. Q32 Bio has a consensus price target of $22.33, suggesting a potential upside of 48.49%. Given Capricor Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Capricor Therapeutics is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Capricor Therapeutics has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

In the previous week, Q32 Bio had 4 more articles in the media than Capricor Therapeutics. MarketBeat recorded 5 mentions for Q32 Bio and 1 mentions for Capricor Therapeutics. Capricor Therapeutics' average media sentiment score of 1.16 beat Q32 Bio's score of 0.32 indicating that Capricor Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Q32 Bio	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 31.3% of Q32 Bio shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by company insiders. Comparatively, 34.5% of Q32 Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Q32 Bio has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	50.71	-$105.04M	-$2.32	N/A
Q32 Bio	$53.74M	4.75	$29.82M	$2.66	5.65

Summary

Q32 Bio beats Capricor Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Q32 Bio compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 31.3% of Q32 Bio shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 34.5% of Q32 Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Q32 Bio has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Q32 Bio	$53.74M	4.75	$29.82M	$2.66	5.65

Q32 Bio has a consensus target price of $22.33, suggesting a potential upside of 48.49%. Given Q32 Bio's stronger consensus rating and higher possible upside, analysts clearly believe Q32 Bio is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Q32 Bio has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Q32 Bio's return on equity of 149.23% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Q32 Bio	N/A	149.23%	34.50%

In the previous week, Q32 Bio had 5 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 5 mentions for Q32 Bio and 0 mentions for Calliditas Therapeutics AB (publ). Q32 Bio's average media sentiment score of 0.32 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Q32 Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Q32 Bio	Neutral

Summary

Q32 Bio beats Calliditas Therapeutics AB (publ) on 14 of the 16 factors compared between the two stocks.

How does Q32 Bio compare to Schrodinger?

Q32 Bio (NASDAQ:QTTB) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

In the previous week, Q32 Bio had 4 more articles in the media than Schrodinger. MarketBeat recorded 5 mentions for Q32 Bio and 1 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.88 beat Q32 Bio's score of 0.32 indicating that Schrodinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Q32 Bio	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Schrodinger	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Q32 Bio has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	4.75	$29.82M	$2.66	5.65
Schrodinger	$255.87M	4.33	-$103.26M	-$1.41	N/A

Q32 Bio has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Schrodinger has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market.

31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 34.5% of Q32 Bio shares are owned by company insiders. Comparatively, 10.1% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Q32 Bio has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Q32 Bio's return on equity of 149.23% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	149.23%	34.50%
Schrodinger	-40.61%	-30.85%	-15.32%

Q32 Bio currently has a consensus price target of $22.33, indicating a potential upside of 48.49%. Schrodinger has a consensus price target of $20.25, indicating a potential upside of 35.00%. Given Q32 Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Q32 Bio is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Q32 Bio beats Schrodinger on 11 of the 15 factors compared between the two stocks.

How does Q32 Bio compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

In the previous week, Q32 Bio had 2 more articles in the media than WAVE Life Sciences. MarketBeat recorded 5 mentions for Q32 Bio and 3 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 1.37 beat Q32 Bio's score of 0.32 indicating that WAVE Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Q32 Bio	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

WAVE Life Sciences currently has a consensus target price of $26.41, suggesting a potential upside of 360.94%. Q32 Bio has a consensus target price of $22.33, suggesting a potential upside of 48.49%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe WAVE Life Sciences is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Q32 Bio has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	25.80	-$204.38M	-$1.06	N/A
Q32 Bio	$53.74M	4.75	$29.82M	$2.66	5.65

WAVE Life Sciences has a beta of -1.29, indicating that its share price is 229% less volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 31.3% of Q32 Bio shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by company insiders. Comparatively, 34.5% of Q32 Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Q32 Bio has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. Q32 Bio's return on equity of 149.23% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-255.70%	-56.76%	-42.80%
Q32 Bio	N/A	149.23%	34.50%

Summary

Q32 Bio beats WAVE Life Sciences on 10 of the 16 factors compared between the two stocks.

How does Q32 Bio compare to Savara?

Savara (NASDAQ:SVRA) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

87.9% of Savara shares are held by institutional investors. Comparatively, 31.3% of Q32 Bio shares are held by institutional investors. 5.3% of Savara shares are held by insiders. Comparatively, 34.5% of Q32 Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Savara has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Savara presently has a consensus target price of $10.14, suggesting a potential upside of 84.75%. Q32 Bio has a consensus target price of $22.33, suggesting a potential upside of 48.49%. Given Savara's stronger consensus rating and higher possible upside, equities analysts clearly believe Savara is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Q32 Bio's return on equity of 149.23% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-87.19%	-66.42%
Q32 Bio	N/A	149.23%	34.50%

In the previous week, Q32 Bio had 5 more articles in the media than Savara. MarketBeat recorded 5 mentions for Q32 Bio and 0 mentions for Savara. Q32 Bio's average media sentiment score of 0.32 beat Savara's score of 0.00 indicating that Q32 Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Savara	Neutral
Q32 Bio	Neutral

Q32 Bio has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Q32 Bio	$53.74M	4.75	$29.82M	$2.66	5.65

Summary

Q32 Bio beats Savara on 9 of the 14 factors compared between the two stocks.

Get Q32 Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QTTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QTTB vs. The Competition

Export

Metric	Q32 Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$255.19M	$3.69B	$6.90B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	5.65	20.49	27.10	23.94
Price / Sales	4.75	300.39	517.51	91.92
Price / Cash	9.93	60.31	26.68	47.25
Price / Book	4.41	7.92	10.66	6.14
Net Income	$29.82M	$23.81M	$3.60B	$331.74M
7 Day Performance	-29.65%	-1.27%	-1.51%	-1.72%
1 Month Performance	26.39%	2.56%	1.11%	-1.44%
1 Year Performance	586.76%	42.49%	23.77%	16.97%

Q32 Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QTTB Q32 Bio	4.7522 of 5 stars	$15.04 -0.1%	$22.33 +48.5%	+587.2%	$255.19M	$53.74M	5.65	39	Gap Down
CAPR Capricor Therapeutics	2.8803 of 5 stars	$20.68 +0.3%	$53.67 +159.5%	+182.6%	$1.20B	$22.27M	N/A	101	Positive News
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
SDGR Schrodinger	2.4711 of 5 stars	$16.13 -1.7%	$20.25 +25.5%	-28.6%	$1.19B	$255.87M	N/A	790	Positive News
WVE WAVE Life Sciences	2.9292 of 5 stars	$6.13 +3.0%	$26.41 +330.9%	-30.2%	$1.18B	$42.73M	N/A	240	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QTTB) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Q32 Bio (QTTB) Competitors

QTTB vs. CAPR, CALT, SDGR, WVE, and SVRA

How does Q32 Bio compare to Capricor Therapeutics?

Summary

How does Q32 Bio compare to Calliditas Therapeutics AB (publ)?

Summary

How does Q32 Bio compare to Schrodinger?

Summary

How does Q32 Bio compare to WAVE Life Sciences?

Summary

How does Q32 Bio compare to Savara?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTTB vs. The Competition

Q32 Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Q32 Bio (QTTB) Competitors

QTTB vs. CAPR, CALT, SDGR, WVE, and SVRA

How does Q32 Bio compare to Capricor Therapeutics?

Is CAPR or QTTB more profitable?

Do analysts recommend CAPR or QTTB?

Which has more risk and volatility, CAPR or QTTB?

Does the media refer more to CAPR or QTTB?

Do institutionals & insiders hold more shares of CAPR or QTTB?

Which has stronger valuation and earnings, CAPR or QTTB?

Summary

How does Q32 Bio compare to Calliditas Therapeutics AB (publ)?

Do institutionals and insiders have more ownership in CALT or QTTB?

Which has more risk and volatility, CALT or QTTB?

Which has stronger earnings and valuation, CALT or QTTB?

Do analysts prefer CALT or QTTB?

Is CALT or QTTB more profitable?

Does the media refer more to CALT or QTTB?

Summary

How does Q32 Bio compare to Schrodinger?

Does the media favor QTTB or SDGR?

Which has better valuation & earnings, QTTB or SDGR?

Which has more volatility & risk, QTTB or SDGR?

Do institutionals & insiders have more ownership in QTTB or SDGR?

Is QTTB or SDGR more profitable?

Do analysts recommend QTTB or SDGR?

Summary

How does Q32 Bio compare to WAVE Life Sciences?

Does the media refer more to WVE or QTTB?

Do analysts rate WVE or QTTB?

Which has preferable earnings & valuation, WVE or QTTB?

Which has more volatility & risk, WVE or QTTB?

Do insiders & institutionals have more ownership in WVE or QTTB?

Is WVE or QTTB more profitable?

Summary

How does Q32 Bio compare to Savara?

Do insiders and institutionals hold more shares of SVRA or QTTB?

Which has more risk and volatility, SVRA or QTTB?

Do analysts rate SVRA or QTTB?

Is SVRA or QTTB more profitable?

Does the media refer more to SVRA or QTTB?

Which has better earnings and valuation, SVRA or QTTB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTTB vs. The Competition

Q32 Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools